RT Journal Article
SR Electronic
T1 SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.24.23287677
DO 10.1101/2023.03.24.23287677
A1 Puhach, Olha
A1 Bellon, Mathilde
A1 Adea, Kenneth
A1 Bekliz, Meriem
A1 Hosszu-Fellous, Krisztina
A1 Sattonnet, Pascale
A1 Coudurier-Boeuf, Sophie
A1 Arm-Vernez, Isabelle
A1 Kaiser, Laurent
A1 Eckerle, Isabella
A1 Meyer, Benjamin
YR 2023
UL http://medrxiv.org/content/early/2023/03/24/2023.03.24.23287677.abstract
AB Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2 is well understood, little is known about the antibodies present on the nasal mucosal surfaces.In this study, we evaluated SARS-CoV-2 mucosal antibodies in response to infection, vaccination, or a combination of both. Paired nasal fluid and serum samples were collected from 136 individuals, which include convalescent, vaccinated, or breakthrough infections.We detected a high correlation between IgG responses in serum and nasal fluids, which were higher in both compartments in vaccinated compared to convalescent participants. Contrary, nasal and systemic SARS-CoV-2 IgA responses were weakly correlated, indicating a compartmentalization between the local and systemic IgA responses. SARS-CoV-2 secretory component IgA (s-IgA) antibodies, present exclusively on mucosal surfaces, were detected in the nasal fluid only in a minority of vaccinated subjects and were significantly higher in previously infected individuals. s-IgA binding antibodies showed significant correlation with neutralizing activity of nasal fluids against SARS-CoV-2 ancestral B.1 and Omicron-BA.5 variant, indicating that s-IgA is the crucial contributor to neutralization in the nasal mucosa. Neutralization against both SARS-CoV-2 strains was higher in the mucosa of subjects with previous SARS-CoV-2 infections compared to vaccinated participants.In summary, we demonstrate that currently available vaccines elicit strong systemic antibody responses, but SARS-CoV-2 infection generates more potent binding and neutralizing mucosal antibodies. Our results support the importance to develop SARS-CoV-2 vaccines that elicit mucosal antibodies.One Sentence Summary SARS-CoV-2 infection or combination of infection and vaccination (hybrid immunity) elicit binding and functional mucosal antibody responses superior of those after systemic vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by the COVID-19 National Research Program (grant number 198412) of the Swiss National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Cantonal Ethics Committee at the University Hospital of Geneva (CCER no. 2020-02323).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsNLFnasal lining fluidtriStrimeric SpikeNPNucleoprotein